Navigation Links
Sangamo BioSciences Reports Third Quarter 2009 Financial Results
Date:11/4/2009

alue=0.02) increase in small unmyelinated nerve fibers in the skin, or intraepidermal nerve fiber density (IENFD), in subjects with DN. Data were also presented that provided additional evidence of the positive effect of SB-509 on large fiber sensory nerve health as measured by improvements in nerve conduction velocity (NCV), in subjects with elevated markers of vascular damage (ICAM-1), and improvements in the muscle components of the neurologic exam (NIS-LL) 30-days after each of the three administrations of SB-509. Together these data confirm the neuroregenerative activity of SB-509 in patients with DN and define a drug-responsive population for future trials.
  • Completion of an underwritten public offering. On October 13, 2009, Sangamo closed an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $7.20 per share resulting in net proceeds of approximately $20.9 million after deduction of underwriting discounts and commissions and other offering expenses.
  • Expansion of licensing agreement with Sigma-Aldrich. Sigma-Aldrich Corporation and Sangamo announced a major expansion of our existing license agreement to include the exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals. Under the expanded agreement, Sigma also obtained rights to certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma made initial payments of $20.0 million to Sangamo, consisting of an upfront license fee of $15.0 million and $5.0 million through the purchase of Sangamo's common stock at $7.86 per share. Sangamo is eligible to earn additional contingent commercial license fees of up to $5.0 million based on certain conditions and thereafter a royalty based upon a percentage of net sales and sublicensing revenue. Sangamo is also eligible to receive commercial milestone payments ranging from $2.0 mil
    '/>"/>

  • SOURCE Sangamo BioSciences, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine news :

    1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
    2. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
    3. Sangamo BioSciences Reports First Quarter 2009 Financial Results
    4. Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
    5. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
    6. Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting
    7. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
    8. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
    9. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
    10. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
    11. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... AZ (PRWEB) January 23, 2015 Hastings and ... injury matters, reports a record number of legal representation client ... speaking, there has been a steady rise in the number ... work and at home throughout the Valley. With that said, ... accident be reviewed by an experienced law firm. Hastings and ...
    (Date:1/22/2015)... its top dressmaking technologies, has been a leading dress supplier ... latest designs of wedding dresses and launching a site-wide promotion ... the fresh new products are designed for 2015, and they ... All the clothes from LunaDress follow up with the latest ...
    (Date:1/22/2015)... 22, 2015 Padre Murphy's and Owner Tom ... Pro Player Health Alliance (PPHA). The PPHA's passion ... getting everyone, including NFL greats, treated for obstructive sleep apnea ... groups supporting the cause in the valley. The most recent ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
    (Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
    Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
    ... ST. LOUIS, June 5 Celebrities, from high-profile,athletes to ... products,including expensive energy drinks and even candy bars, are ... it is the nutrient fad of the,moment., Fleming ... on the market ranged from 40% all the way ...
    ... Diana Kirschner Explains the Psychology Behind It, NEW ... an estimated,$55.7 million for its opening weekend, beating out ... other romantic comedy has ever,opened with such a lucrative ... occurring," says Dr. Diana Kirschner, psychologist and,recurring relationship expert ...
    ... Expects FDA to Request Additional Safety Study Prior to ... Inc.,(Nasdaq: IDEV ) today announced that based on ... (FDA) regarding the NDA filing for,NEBIDO(R), the Company expects ... safety data prior to approving NEBIDO. The Company,currently believes ...
    ... risk of developing rheumatoid arthritis by up to 50%, ... of the Rheumatic Diseases. , The Scandinavian researchers base ... in two separate studies, which assessed environmental and genetic ... the participants (1650) had the disease and had been ...
    ... FALLS CHURCH, Va., June 4 CSC (NYSE: ... Dell Inc. (Nasdaq: DELL ) to design and,deploy ... and,complexity out of their information technology (IT) environment and ... help clients,simplify processes associated with IT and enhance innovation ...
    ... to Ensure Equitable Protections,for All Americans and Their ... America,s,Health (TFAH) issued the following statement on the ... Services(HHS) Draft Guidances to Assist in,Preparation for an ... government must do all it can to ensure ...
    Cached Medicine News:Health News:The Vitamin B12 Craze - Super Nutrient or Super Hype? 2Health News:Why is the Sex & the City Movie a Mega-Blockbuster? 2Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 2Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 3Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 4Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 5Health News:Regular tipple may curb risk of rheumatoid arthritis 2Health News:CSC to Simplify IT From Desktop to Data Center 2Health News:Trust for America's Health on New HHS Influenza Pandemic Draft Guidance 2
    (Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
    (Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
    (Date:1/23/2015)... BIRMINGHAM, Ala. , Jan. 23, 2015 Gem ... (STS) patients have been enrolled into the Company,s Phase ... efficacy and safety of Gem,s lead compound, GPX-150 (an ... for advanced or metastatic disease. Logo - ...
    Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
    ... Bayer HealthCare LLC announced today that it has ... and Farnam Companies Inc. over Farnam,s advertising for its ... of the settlement, Farnam has agreed to withdraw the ... campaign included claims that Bio Spot® was "as effective ...
    ... CLARA, Calif., June 17, 2011 NewCardio, Inc., (OTC ... that Vincent Renz, Chief Executive Officer, is scheduled to ... Conference is on June 22 and 23, 2011, at ... 3:30 p.m. ET on Wednesday, June 22. ...
    Cached Medicine Technology:Bayer Announces Farnam Companies' Agreement to Halt Disputed Bio Spot® Ads 2NewCardio to Present at Wells Fargo Securities Healthcare Conference 2NewCardio to Present at Wells Fargo Securities Healthcare Conference 3
    ... The Optimal temporary implant for use with ... The pupil dilator type 5S is a ... of the pupil during phacoemulsification. It is ... use. Indication: Expansion of the pupil during ...
    ... coated with a thin layer ... the surface slick as glass ... prevent debris from collecting on ... For partial stenosis. Silicone with ...
    For use with Crawford Intubation Systems....
    ... prolene as thread-guide reducing time and trauma ... Probe is inserted into the nasolacrimal duct ... through it. The probe is then withdrawn ... silicone tubing in place. Canalicular Laceration or ...
    Medicine Products: